文献速递哮喘

哮喘进展与死亡率:吸入性糖皮质激素的作用

Asthma progression and mortality: the role of inhaled corticosteroids.
PubMed 文献 · Eur Respir J · 2019-07-18

本综述评估药物干预尤其是吸入性糖皮质激素(ICS)对哮喘进展和死亡率的影响。过去30年哮喘死亡率大幅下降,部分归因于ICS的广泛使用;ICS改善哮喘控制、减少急性发作的证据充分,但预防肺功能下降的证据尚不充分。

要点

  • ICS改善哮喘控制、减少急性发作的证据充分。
  • ICS预防肺功能下降的证据不充分,但减少重症急性发作可能部分预防下降。
  • 管理数据库研究支持ICS降低哮喘死亡率,但难以在前瞻性试验中验证。

核心结论

  • ICS对改善哮喘控制、减少急性发作有充分证据,对预防肺功能下降证据不充分,对降低哮喘死亡率有管理数据库支持。

研究设计与样本

  • 综述,评估药物干预尤其是ICS对哮喘进展和死亡率的作用。

主要发现

  • 过去30年哮喘死亡率大幅下降,与ICS更广泛使用相关。
  • ICS改善症状、肺功能并减少急性发作的证据充分。
  • ICS预防肺功能下降的证据不充分。
  • 重症急性发作与肺功能更快速下降相关,ICS通过减少重症急性发作可能部分预防下降。
  • 管理数据库研究支持ICS降低哮喘死亡率,但哮喘死亡率罕见,难以在前瞻性试验中验证。

临床怎么用

  • ICS应作为改善哮喘控制和减少急性发作的核心治疗。
  • 对重症急性发作高风险患者,ICS可能有助于减缓肺功能下降。
  • 管理数据库证据支持ICS降低哮喘死亡率,但需结合个体评估。

局限性

  • ICS预防肺功能下降的证据不充分。
  • 哮喘死亡率罕见,难以在前瞻性试验中验证ICS的死亡率获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Overall, asthma mortality rates have declined dramatically in the last 30 years, due to improved diagnosis and to better treatment, particularly in the 1990s following the more widespread use of inhaled corticosteroids (ICSs). The impact of ICS on other long-term outcomes, such as lung function decline, is less certain, in part because the factors associated with these outcomes are incompletely understood. The purpose of this review is to evaluate the effect of pharmacological interventions, particularly ICS, on asthma progression and mortality. Furthermore, we review the potential mechanisms of action of pharmacotherapy on asthma progression and mortality, the effects of ICS on long-term changes in lung function, and the role of ICS in various asthma phenotypes.Overall, there is compelling evidence of the value of ICS in improving asthma control, as measured by improved symptoms, pulmonary function and reduced exacerbations. There is, however, less convincing evidence that ICS prevents the decline in pulmonary function that occurs in some, although not all, patients with asthma. Severe exacerbations are associated with a more rapid decline in pulmonary function, and by reducing the risk of severe exacerbations, it is likely that ICS will, at least partially, prevent this decline. Studies using administrative databases also support an important role for ICS in reducing asthma mortality, but the fact that asthma mortality is, fortunately, an uncommon event makes it highly improbable that this will be demonstrated in prospective trials.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. O'Byrne P, Fabbri LM, Pavord ID, et al. Asthma progression and mortality: the role of inhaled corticosteroids. Eur Respir J. 2019. PMID: 31048346. doi:10.1183/13993003.00491-2019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。